Sign In

Brett Wingeier, Ph.D.

I turn data into life-changing products.

Brett Wingeier is a seasoned professional with a diverse background in science, engineering, and product leadership, known for turning data into life-changing products.

With over 25 years of experience, he excels in research, development, and product management of high-reliability, data-intensive hardware/software solutions for medical applications.

Brett has a strong foundation in biomedical engineering, holding a Ph.D. from Tulane University and has further honed his skills through programs at Stanford University and Swinburne University of Technology.

As a scientist, Brett specializes in analyzing complex data using tools like FFTs, GEEs, and TensorFlow, while as an engineer, he designs and implements solutions across hardware, software, embedded systems, and more.

His expertise spans mission-critical embedded systems, Python, RTOS, BLE, TinyML, and he brings a business-oriented approach to product development, focusing on customer needs and effective communication.

Prior to founding LT2 Labs, Brett was instrumental in the success of Magnus Medical, a company dedicated to mental health solutions, where he led the development of FDA-cleared products for major depression treatment.

He also played key roles at Halo Neuroscience, driving R&D and manufacturing operations for wearable neurotech products in the healthtech market.

Brett's impressive career includes notable positions like Vice-President of Research and Development at NeuroPace, CTO, and CEO at Magnus Medical, and Founder at Halo Neuroscience.

He is a registered patent agent with over 70 US patents to his name, underscoring his innovative spirit and contribution to the field.

Throughout his career, Brett has demonstrated a commitment to creating impactful solutions that merge cutting-edge technology with a deep understanding of human physiology.

Highlights

Oct 29 · linkedin

Today we're proud to launch Magnus Medical and share that we’ve been granted Breakthrough Device Designation from the FDA for our individualized, non-invasive, investigational #neuromodulation technology intended for people with major depressive disorder who have not responded to existing treatments. Equally exciting is our exclusive license for the SAINT technology, which yielded 79% remission of treatment-resistant #depression in a randomized controlled trial published today on the American Journal of Psychiatry website.

I couldn't ask for a better team and more meaningful project. Many thanks to the friends and colleagues who have taken us this far, a generation of scientists and clinicians who have laid the groundwork for these breakthroughs, and to JAZZ Venture Partners and Red Tree Venture Capital for the support and guidance. Together, we can restore and sustain #mentalhealth and make a lasting impact for good.

More: http://ow.ly/Waaq50GAEJ5

#brainhealth #fMRI #neuroscience #psychiatry #medicaldevices

Nov 6 · linkedin

Looking forward to #IEEETechEthics panel on 8 Nov as we discuss implications of #brain #stimulation for #athletes at the intersection of #neuroscience, #ethics, and #sport. Register to join the live stream for free at: https://lnkd.in/dqxAV_H. #IEEE #neuroethics

Brett Wingeier, Ph.D.
Add to my network

Location

San Francisco, California, United States